Breckenridge Pharmaceutical, Inc. announced the launch of Lacosamide Tablets, USP (generic version of Vimpat®). The product was developed and will be manufactured by MSN Laboratories Private Limited and marketed by Breckenridge in the US.
Breckenridge's Lacosmide Tablets, USP are available in 50mg, 100mg, 150mg and 200mg strengths, and contained in bottle configurations of 60 and 500 counts. According to industry sales data, Vimpat had annual sales of $1.7B during the twelve months ending February 2022.
Breckenridge Pharmaceutical is a subsidiary of Towa Pharmaceutical (Osaka, Japan), who partners with manufacturers nationwide and around the world to bring generic pharmaceuticals to U.S. patients. MSN Group is a pharmaceutical company based out of Hyderabad, India. The organization has 16 manufacturing facilities (twelve API and four finished dosage facilities) in India and USA. The Group has an integrated R&D center for both API and formulation under one roof, dedicated to research and development of pharmaceuticals.